Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX

Next Previous
Trial Profile

Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Girentuximab Zr-89 (Primary)
  • Indications Adenocarcinoma; Breast cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Liver cancer; Lung cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Vulval disorders
  • Focus Pharmacokinetics
  • Acronyms STARBURST
  • Sponsors Telix Pharmaceuticals

Most Recent Events

  • 01 Apr 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
  • 28 Mar 2024 According to a Telix Pharmaceuticals media release, data from this study will be presented at the 39th Annual European Association of Urology Congress (EAU24), being held in Paris (France) from 5-8 April 2024.
  • 18 Jun 2023 According to a Telix Pharmaceuticals Media Release, Dr Jackson Kiser is the Principal Investigator for the STARBURST study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top